| Literature DB >> 26474075 |
Marylin Hidalgo1, Lina P Carvajal2, Sandra Rincón2, Álvaro A Faccini-Martínez1, Alba A Tres Palacios1, Marcela Mercado3, Sandra L Palomá1, Leidy X Rayo1, Jessica A Acevedo1, Jinnethe Reyes2, Diana Panesso4, Paola García-Padilla5, Carlos Alvarez5, Cesar A Arias4.
Abstract
We aimed to determine the prevalence of MRSA colonization and examine the molecular characteristics of colonizing isolates in patients receiving hemodialysis and HIV-infected in a Colombian hospital. Patients on hemodialysis and HIV-infected were prospectively followed between July 2011 and June 2012 in Bogota, Colombia. Nasal and axillary swabs were obtained and cultured. Colonizing S. aureus isolates were identified by standard and molecular techniques. Molecular typing was performed by using pulse-field gel electrophoresis and evaluating the presence of lukF-PV/lukS-PV by PCR. A total of 29% (n = 82) of HIV-infected and 45.5% (n = 15) of patients on hemodialysis exhibited S. aureus colonization. MSSA/MRSA colonization was observed in 28% and 3.6% of the HIV patients, respectively and in 42.4% and 13.3% of the hemodialysis patients, respectively. Staphylococcal cassette chromosome mec typing showed that four MRSA isolates harbored the type IV cassette, and one type I. In the hemodialysis group, two MRSA isolates were classified as belonging to the USA300-LV genetic lineage. Conversely, in the HIV infected group, no colonizing isolates belonging to the USA300-Latin American Variant (UDA300-LV) lineage were identified. Colonizing isolates recovered from the HIV-infected group belonged to the prevalent hospital-associated clones circulating in Latin America (Chilean [n = 1] and Pediatric [n = 2]). The prevalence of MRSA colonization in the study groups was 3.6% (HIV) and 13.3% (hemodialysis). Surveillance programs should be implemented in this group of patients in order to understand the dynamics of colonization and infection in high-risk patients.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26474075 PMCID: PMC4608721 DOI: 10.1371/journal.pone.0140748
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
General characteristics of HIV-infected patients evaluated in this study.
| Characteristic | HIV patientsn = 283 (%) | |
|---|---|---|
| Gender | Male | 241 (85,2) |
| Female | 42 (14,8) | |
| Age | 20–40 years old | 176 (62,2) |
| > 40 years old | 107 (37,8) | |
| Frequency of medical control | Weekly | 2 (0,7) |
| Monthly | 208 (73,5) | |
| Bimonthly | 61(21,6) | |
| Biannual | 4 (1,4) | |
| Others | 8 (2,8) | |
| Infection in 6 months | No | 251 (88,7) |
| Yes | 32 (11,3) | |
General characteristics of dialysis patients evaluated in this study.
|
|
| |
| Gender | Male | 22 (66,7) |
| Female | 11 (33,3) | |
| Age | 20–40 years old | 8 (24,2) |
| > 40 years old | 25 (75,8) | |
| Time in renal unit | 1 to 71 months | 24 (72,7) |
| More than 71 months | 9 (27,3) | |
| Frequency HD | 2 days per week | 1 (3) |
| 3 days per week | 32 (97) | |
| Comorbidities (# of patients) | No | 3 (9,1) |
| Yes | 30 (90,9) | |
| Diabetes (12) | ||
| Hypertension (5) | ||
| Cancer (2) | ||
| Vascular disease (2) | ||
| Chronic kidney disease and end-stage renal disease (9) | ||
| Venous catheter | 3 (9,1) | |
| AVF | 30 (90,9) | |
| Hospitalization in last 6 months | No | 19 (57,6) |
| Yes | 14 (42,4) | |
| Infection in last 6 months | No | 25 (75,8) |
| Yes | 8 (24,2) | |
Notes: HD: Hemodialysis, AVF: Arteriovenous fistula.
Time in renal Unit: 71 months (ca. 6 years) is the average time that most patients
spend in the dialysis unit before they have complications including death
Characteristics of MRSA strains isolated from the two populations evaluated.
| Interpretation of antibiotic susceptibility | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Population group | OXA | ERY | GEN | CIP | TET | CLI | SXT | VAN | CHL | RIF | LIN | PVL (+/-) | SCCmec type | Clonal identification |
| HIV infection | R | R | R | R | S | R | S | S | S | S | S | (-) | I | Chilean |
| HIV infection | R | R | R | R | S | R | S | S | S | S | S | (-) | IV | Pediatric |
| HIV infection | R | R | R | R | S | R | S | S | S | S | S | (-) | IV | Pediatric |
| Hemodialysis | R | S | S | S | S | S | S | S | S | S | S | (+) | IV | USA300-LV |
| Hemodialysis | R | S | S | S | S | S | S | S | S | S | S | (+) | IV | USA300-LV |
OXA: oxacillin, ERY: erythromycin, GEN: gentamicin, CIP: ciprofloxacin, SXT: trimethoprim-sulfamethoxazole, VAN: vancomycin, CHL: chloramphenicol, RIF: rifampin, LIN: linezolid